BRD2 and neoplasm: However, as histological assessment of tumor regression indicated moderate or poor response to NAT in the majority of cases (CAP‐2/3), changes in the expression of stoma‐related proteins are likely more pronounced in the small proportion of PDAC patients in whom NAT results in complete or near complete tumor regression (CAP‐0/1).